Augmentin for Infected Wound
For an adult with a soft-tissue wound infection who is not allergic to penicillins, Augmentin (amoxicillin-clavulanate) 875/125 mg orally twice daily for 5-10 days is appropriate for mild to moderate nonpurulent cellulitis or surgical wound infections, but it is NOT the first-line choice for purulent infections where MRSA coverage is needed.
When Augmentin IS Appropriate
Augmentin is specifically recommended for:
- Nonpurulent cellulitis (no drainage, no abscess) where β-hemolytic streptococci are the primary concern 1, 2, 1
- Animal or human bite wounds requiring coverage of mixed aerobic-anaerobic flora including Pasteurella species and oral anaerobes 3, 4
- Surgical site infections after operations involving nonsterile tissue (colonic, vaginal, biliary, or respiratory mucosa) where mixed flora is expected 5, 3
When Augmentin is NOT Appropriate
Do not use Augmentin as empiric monotherapy for:
- Purulent cellulitis (cellulitis with purulent drainage or exudate) where CA-MRSA is likely 1, 2, 1
- Abscesses requiring drainage, unless combined with MRSA-active agents
- Complicated skin infections in hospitalized patients where broader coverage is needed
The 2011 IDSA guidelines explicitly state that for nonpurulent cellulitis, empirical therapy should target β-hemolytic streptococci, and MRSA coverage should only be added if the patient fails β-lactam therapy 1, 2, 1. Augmentin fits this role perfectly.
Dosing Recommendations
Standard adult dosing:
- Augmentin 875/125 mg orally twice daily 3, 4
- Alternative: Augmentin 500/125 mg three times daily for less severe infections
Duration:
- 5-10 days for uncomplicated soft-tissue infections, individualized based on clinical response 1, 2, 1
- 7-14 days for complicated infections requiring hospitalization 1, 2
- Take at the start of meals to minimize gastrointestinal intolerance and enhance clavulanate absorption 6
Clinical Decision Algorithm
Step 1: Classify the wound infection
- Purulent (drainage/exudate present) → NOT Augmentin alone; use clindamycin, TMP-SMX, or doxycycline for MRSA coverage 1, 2, 1
- Nonpurulent (no drainage, simple cellulitis) → Augmentin is appropriate 1, 2
- Bite wound (animal/human) → Augmentin is first-line 3, 4
Step 2: Assess severity
- Mild-moderate outpatient infection → Oral Augmentin 875/125 mg twice daily
- Severe or systemic toxicity → Consider hospitalization with IV therapy (ampicillin-sulbactam 1.5-3 g every 6 hours) 3, 4
Step 3: Monitor response
- If no improvement after 48-72 hours on Augmentin → Add MRSA coverage or switch to MRSA-active agent 1, 2, 1
- If improving → Complete 5-10 day course
Important Caveats
Augmentin misses MRSA coverage entirely 3, 4. In areas with high CA-MRSA prevalence or in patients with risk factors (recent antibiotics, healthcare exposure, injection drug use), empiric MRSA coverage should be considered from the start. If dual coverage for streptococci and MRSA is needed, the guidelines recommend TMP-SMX or doxycycline plus amoxicillin (not Augmentin, as the clavulanate adds unnecessary cost without benefit for this indication) 1, 2, 1.
For bite wounds specifically, Augmentin provides excellent coverage against Pasteurella multocida, oral anaerobes, and Eikenella corrodens (in human bites), making it the preferred single-agent oral option 3, 4. Prophylactic antibiotics for bite wounds are most beneficial for high-risk wounds (hand injuries, deep punctures, immunocompromised hosts) presenting within 12-24 hours 3.
Storage and adherence matter: Augmentin suspension degrades rapidly in hot environments, and missed doses lead to subtherapeutic levels and treatment failure 7. Counsel patients to refrigerate reconstituted suspension and complete the full course.
Surgical site infections developing >48 hours postoperatively with fever >38.5°C or tachycardia >110 bpm may benefit from a short course (24-48 hours) of antibiotics after incision and drainage, but antibiotics alone without drainage are insufficient 3. For clean procedures without entry into nonsterile areas, Augmentin may be excessive; simpler anti-staphylococcal agents suffice 3.